NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference, and the Leerink Global Healthcare Conference.
| Details of the Presentations: | |
| Title: | BIO CEO & Investor Conference |
| Date: | Monday, February 9 |
| Time: | 4:00pm Eastern |
| Location: | Louis XVI Room, Waldorf Astoria Hotel, New York City |
| Title: | Leerink Global Healthcare Conference |
| Date: | Wednesday, February 11 |
| Time: | 8:50am Eastern |
| Location: | Carnegie Suite, Waldorf Astoria Hotel, New York City |
| Webcast: | http://leerink.metameetings.com/confbook/healthcare15/directlink.php?ticker=OHRP |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead product, Squalamine, is currently being studied as an eye drop formulation (OR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.